Navigation Links
Combination of Tratuzumab and Chemotherapy Yields Better Results for Breast Cancer

A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.

At the ESMO Conference Lugano, Issa Dahabreh from the University of Athens reported the results of a meta-analysis of 5 trials involving more than 13,000 women whose breast cancer was amenable to surgery.

All the trials compared disease-free survival, overall survival and the risk of locoregional and distant recurrence of breast cancer in women given adjuvant chemotherapy alone or chemotherapy plus trastuzumab, after breast surgery.

Up to a quarter of all breast cancers express large amounts of the HER2 protein or carry multiple copies of the HER2 gene. Those cancers tend to be associated with aggressive disease, a higher likelihood of recurrence and a decreased response to treatment. Trastuzumab is a monoclonal antibody that directly targets part of the HER2 tyrosine kinase receptor.

The results showed that combining trastuzumab with chemotherapy results in a -34% reduction in mortality and a 38% increase in disease-free survival, Dahabreh said. Those survival benefits were accompanied by decreases in the risk of both locoregional and distant recurrences of the cancer.

Taken together, these results confirm that the administration of trastuzumab in combination with chemotherapy should be the standard choice for the treatment of women with HER2 positive early stage disease, especially those with limited cardiovascular comorbidities, Dahabreh said.

This is the first meta-analysis of current published trials on the adjuvant use of trastuzumab. The results are of great clinical value since they indicate that treatment with trastuzumab results in major survival benefit in women with an aggressive disease subtype.

The level of effectiveness demonstrated by this ana lysis is largely unprecedented in the treatment of solid tumors, the authors say, and highlights the potential of implementing targeted agents with cytotoxic chemotherapy.

More information about ECLU is available at http: www.esmo.org/activities/ecluconference/.


'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Drug Combinations May Boost Stroke Risk
3. Combination therapy to treat breast cancer
4. Combination regime may work against prostate cancer
5. Smoking and Breast Cancer - A Deadly Combination
6. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
7. A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer
8. Combination Therapy Effective In Improving Lung Cancer Survival
9. Combination Therapy Found To Improves Stroke Recovery
10. Combination Therapy Found To Be More Effective In Treating Brain Cancer
11. Combination of Clopidogrel-aspirin is better for preventing stroke than only aspirin
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... 21, 2017 , ... The Karen Miller Agency, a central ... the greater Birmingham area, is joining the Chris Hammond Youth Foundation in a ... region. , The Chris Hammond Youth Foundation maintains athletic facilities in rural areas ...
(Date:7/21/2017)... Grove, Ill. (PRWEB) , ... July 21, 2017 , ... ... & Fabric Liquid eco-friendly odor-control solution for colleges and universities at the ... safely and effectively eliminate severe cannabis and tobacco smoke odors without the use of ...
(Date:7/21/2017)... Norwalk, Connecticut (PRWEB) , ... July 21, 2017 , ... ... data from HealthCareMandA.com . The number of hospital acquisitions rose to 23 in ... quarter of 2017, and up 15% from the 20 announced deals in the year-ago ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed ... of its ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada ... Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... received a $5,000 grant from the C. R. Bard Foundation, Inc. ... at Somerset Hills , a service available through the nonprofit home care agency. ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... manufacturing network, the Company will be ceasing operations and ... Huntsville, Alabama . The closure of the facilities ... to 18 months. The Huntsville ... products and these restructuring actions are intended to better ...
(Date:7/20/2017)...  Prime Therapeutics LLC (Prime) released this statement from its ... Institute for Clinical and Economic Review,s (ICER) public meeting ... value of abuse-deterrent formulations (ADF) of opioids. Prime was the ... meeting. "The ICER ... the use of abuse-deterrent formulations (ADF) in opioids in terms ...
(Date:7/17/2017)... -- MedX Holdings, Inc., the manufacturer and global distributor of ... today announced the national roll out of its MedX ... standard for the treatment of low back injuries and ... How it works: MedX ... who prescribe the MedX Home Back Machine Program for ...
Breaking Medicine Technology: